DaVita Inc presents a distinctive financial profile within the dialysis services sector, characterized by an exceptional ROE of 181.22% that significantly exceeds typical healthcare services benchmarks. This elevated return metric stems from a capital structure featuring a book value per share of just $1.50 against a current trading price of $240.09, resulting in a price-to-book ratio of 101.25. The company's substantial debt-to-equity ratio of 77.99 amplifies equity returns while introducing meaningful leverage considerations into the fundamental profile.

The model indicates several operational strengths based on recent performance data:

• Revenue growth of 6.68% year-over-year demonstrates sustained market demand in the renal care segment, translating to consistent operating margin expansion at 14.98%
• Trading near the upper bound of its 52-week range ($101.0–$244.49), the security has appreciated 142% from its annual low, reflecting improved fundamental sentiment
• Defensive characteristics surface through a beta of 0.87, positioning the equity as less volatile than broader market indices during periods of heightened uncertainty
• Net margin of 5.65% and trailing P/E of 19.66 suggest disciplined cost management relative to revenue scale

Systematic screening flags concentrated risk factors including the elevated leverage profile and minimal tangible book value, which constrain financial flexibility during potential reimbursement pressure cycles. The current ratio of 1.29 provides modest liquidity cushion for near-term obligations.

Relative to diversified healthcare peers including CI, DGX, and LH, DaVita operates with higher operational focus in dialysis services, creating distinct margin dynamics and regulatory exposure patterns within the Health Care sector framework.